FMT+SOX+Sintilimab As First-line Treatment for Advanced Gastric Cancer

the investigators plan to initiate a prospective, multicenter, randomized, double-blind, placebo-controlled phase II study, recruiting 198 patients with advanced gastric/gastroesophageal junction adenocarcinoma who have not received prior treatment. Randomly divided into two groups, one group is the group of fecal microbiota transplantation(FMT)+SOX+Sintilimab, and the other group is the group of SOX+Sintilimab. Compare the 2-year OS rates of the two groups to verify whether the addition of FMT to first-line treatment can improve the prognosis of gastric cancer patients.

Trial Details

NCT ID
NCT06405113
Phase
PHASE2
Sponsor
Changzhou No.2 People's Hospital
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy
Locations (sample)
  • Changzhou, China|31.77359,119.95401

Key Eligibility Criteria

  • Subjects aged 18-80 (including 18 and 80 years old);
  • Understand the research steps and content, and voluntarily sign a written informed consent form;
  • Non resectable Her-2 negative advanced or metastatic gastric/gastroesophageal junction adenocarcinoma confirmed by histopathology and/or cytology, …
  • At least one measurable lesion, according to RECIST 1.1 standard;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →